Premium
Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized controlled trials
Author(s) -
Seshasai S. R. K.,
Bennett R. L.,
Petrie J. R.,
Bengus M.,
Ekman S.,
Dixon M.,
Herz M.,
Buse J. B.,
Ray K. K.
Publication year - 2015
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12448
Subject(s) - medicine , type 2 diabetes , randomized controlled trial , odds ratio , myocardial infarction , clinical endpoint , confidence interval , diabetes mellitus , endocrinology
Aims To study the short‐term cardiovascular effects of the once‐weekly glucagon‐like peptide‐1 receptor agonist taspoglutide. Methods We conducted a meta‐analysis of individual‐participant data from nine randomized controlled trials in the T‐E merge programme, which assessed the efficacy and safety of taspoglutide in type 2 diabetes. Our primary outcome was a composite of death from cardiovascular disease ( CVD ) and acute myocardial infarction, stroke and hospitalization for unstable angina. Results Overall, 7056 individuals were included in the analysis, and there were 67 primary endpoint events during 7478 person‐years of follow‐up (40 vs 27 events in the intervention vs control groups, respectively). The odds ratio for the composite endpoint among people randomized to taspoglutide was 0.94 (95% confidence interval 0.57–1.56), which was robust across multiple subgroups. Longer‐term data were not available as the development of taspoglutide was stopped because of gastrointestinal intolerance and serious hypersensitivity reactions. Conclusions The available data suggest that short‐term, once‐weekly administration of taspoglutide was not associated with an excess risk of CVD , and provide insights relevant to the development of other novel once‐weekly incretin mimetics.